Trial reportJournal of hepatology2003
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
Trial report in Journal of hepatology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Potential Role of Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Ascites in Cirrhotic Patients
Phase 4 Study on the Comparison Between Combined Versus Sequential Diuretic Treatment of Moderate Ascites in Nonazotemic Patients With Cirrhosis
Who cites it
46 citing papers in PubMed, 6 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- Guideline
- Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.Clinical and molecular hepatology · 2018Guideline
- Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).Wiener klinische Wochenschrift · 2017Guideline
- Revision and update on clinical practice guideline for liver cirrhosis.The Korean journal of hepatology · 2012Guideline
- Guideline
- Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.BMC gastroenterology · 2020Trial
- KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026.Clinical and molecular hepatology · 2026Article
- Refractory Ascites and the Alfapump.Gastro hep advances · 2026Review
- Sodium-Glucose Cotransporter 2 Inhibitors and Serious Liver Events in Patients With Cirrhosis.JAMA network open · 2025Article
- Update on the Complications and Management of Liver Cirrhosis.Medical sciences (Basel, Switzerland) · 2025Review
- Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real-World Retrospective Study.The Prostate · 2025Article
- Outpatient management after hospitalisation for acute decompensation of cirrhosis: A practical guide.World journal of hepatology · 2024Review
- Advances in the management of complications from cirrhosis.Gastroenterology report · 2024Review
- [Hemodynamic Changes in Chronic Liver Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV).Wiener klinische Wochenschrift · 2023Article
- Asia-Pacific association for study of liver guidelines on management of ascites in liver disease.Hepatology international · 2023Article
- Hypertension: sex-related differences in drug treatment, prevalence and blood pressure control in primary care.Journal of human hypertension · 2023Review
- Urea Transporter Inhibitor 25a Reduces Ascites in Cirrhotic Rats.Biomedicines · 2023Article
- Management of Liver Decompensation in Advanced Chronic Liver Disease: Ascites, Hyponatremia, and Gastroesophageal Variceal Bleeding.Clinical drug investigation · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThe most rational treatment of moderate ascites is spironolactone alone or in combination with furosemide. However, it is unknown which of these two treatment schedules is preferable.
methodsOne hundred nonazotemic cirrhotic patients with moderate ascites were randomly assigned to be treated with spironolactone and furosemide (Group 1: 50 patients) or with spironolactone alone (Group 2: 50 patients). If no response was obtained, the doses of diuretics were increased up to 400 mg/day of spironolactone and 160 mg/day of furosemide. In patients of group 2 not responding to 400 mg/day of spironolactone, furosemide was added. In cases with an excessive response, the dosage of diuretics was reduced.
resultsThe response rate (98% in Group 1 vs. 94% in Group 2), the rapidity of ascites mobilization and the incidence of complications induced by diuretic therapy was similar in both groups. The need to reduce the diuretic dosage was significantly higher in Group 1 than Group 2 (68% vs. 34%; P=0.002).
conclusionsIn the treatment of moderate ascites, spironolactone alone seems to be as safe and effective as spironolactone associated with furosemide. Since spironolactone alone requires less dose adjustment, it would be more suitable for treating ascites on an outpatient basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.